Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has announced that a Meeting of the Board of Directors will be held on Thursday, February 12, 2026. The primary purpose of this meeting is to consider and approve the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine-months ending December 31, 2025. In accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the company's securities will be closed from January 1, 2026, to February 14, 2026, inclusive.
